Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corp (QTRX) disclosed that a director acquired common stock through board compensation. On 10/01/2025, the director received 2,084 shares of common stock granted in lieu of cash fees for service on the Board and its committees for the third quarter of 2025. The grant was valued at the $5.54 closing price on the Nasdaq Global Market on that date.
Following this transaction, the director’s beneficial ownership was 29,488 shares, held directly, which includes 24,464 restricted stock units.
Quanterix Corporation director William P. Donnelly received 5,076 shares of common stock on 10/01/2025 as compensation in lieu of cash for board and committee service for the third quarter of 2025. The shares were recorded at the closing price of $5.54 on the Nasdaq Global Market for that date. Following the grant, Mr. Donnelly beneficially owns 148,374 shares, which include 12,955 restricted stock units. The Form 4 was filed individually and signed via attorney-in-fact on behalf of the reporting person.
Mendel Scott, a director of Quanterix Corp (QTRX), received 2,084 shares of common stock on 10/01/2025 as stock issued in lieu of cash board fees for Q3 2025 at a closing price of $5.54. Following the issuance, Mr. Scott beneficially owns 30,737 shares, which include 24,464 restricted stock units. The Form 4 was signed on behalf of the reporting person by Brian Keane, Attorney-in-Fact. The filing discloses no derivative transactions, option grants, or other cash purchases in this report.
Quanterix Corporation director Walt David R received 2,594 shares of common stock on 10/01/2025 as compensation in lieu of cash for third‑quarter 2025 board and committee fees, at the Nasdaq closing price of $5.54 per share. After the grant, the reporting person beneficially owns 1,871,675 shares, which include 7,435 restricted stock units. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. The filing discloses a single non‑derivative acquisition and explains the grant source and price; no options, dispositions, or additional derivative transactions are reported.
Quanterix Corporation adjourned its shareholder meeting and scheduled an adjourned session for shareholders who pre-register by 10:00am ET on September 28, 2025 at the provided registration URL. The company reported that at the original meeting time shareholders who voted were overwhelmingly in favor of two proposals to eliminate supermajority vote requirements, with 99% of votes cast supporting those two proposals. However, the shares that voted in favor represented 74.8% of the company’s common stock outstanding. The filing is signed by Vandana Sriram, Chief Financial Officer, and lists contact and filing references.
Quanterix Corporation filed an amendment to a current report to provide additional financial details related to its acquisition of Akoya Biosciences, Inc. The acquisition of Akoya was completed on July 8, 2025 under an Amended and Restated Agreement and Plan of Merger dated April 28, 2025 among Quanterix, a merger subsidiary, and Akoya.
This amendment adds unaudited pro forma condensed combined financial statements for Quanterix and Akoya for the year ended December 31, 2024 and as of and for the six months ended June 30, 2025, which are included as Exhibit 99.1. The historical financial statements of Akoya were previously filed in a post-effective amendment to Quanterix’s Form S-4 registration statement and are incorporated by reference rather than repeated here.
Sriram Vandana, Chief Financial Officer of Quanterix Corporation (QTRX), reported a sale of common stock on 09/15/2025. The filing shows 229 shares disposed at a price of $4.97 per share, marked with code F and explained as shares withheld by the company to cover tax obligations arising from the vesting of 777 restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 86,971 shares, which the filing notes includes 71,670 RSUs. The form is signed by an attorney-in-fact on behalf of the reporting person and reflects a routine tax-withholding disposition rather than an open-market sale for cash.
Toloue Masoud, who serves as President & CEO and a director of Quanterix Corporation (QTRX), reported a sale of 1,242 shares of common stock at $4.97 per share. The filing states these shares were disposed (code F) and that 3,722 restricted stock units vested, with shares withheld solely to cover tax obligations related to that vesting. After the reported transaction Masoud is shown as beneficially owning 513,192 shares in total, which include 224,330 restricted stock units.
Quanterix Corp (QTRX) insider purchase by CFO: The filing shows Sriram Vandana, Chief Financial Officer, acquired 4,150 shares of Quanterix common stock on 09/12/2025 at $4.79 per share. After the transaction Vandana beneficially owned 87,200 shares in total, which the filing notes includes 72,447 restricted stock units. The Form 4 was submitted with a signature executed by an attorney-in-fact on 09/15/2025. The document records a single non-derivative purchase and lists no derivative transactions or additional amendments.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
